Profile data is unavailable for this security.
About the company
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
- Revenue in CNY (TTM)1.29bn
- Net income in CNY-15.12m
- Incorporated2012
- Employees2.70k
- LocationNanjing Vazyme Biotech Co Ltd1-6F, East Section, Building C1-2Hongfeng Science and Technology ParkKechuang Road, Economic and TechnologicaNANJING 210000ChinaCHN
- Phone+86 2 585771179
- Fax+86 2 585771171
- Websitehttps://www.vazyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry Co., Ltd | 5.47bn | 339.08m | 8.96bn | 4.33k | 26.41 | 1.60 | -- | 1.64 | 0.3321 | 0.3321 | 5.36 | 5.48 | 0.6331 | 4.13 | 4.89 | 1,264,384.00 | 3.33 | 6.23 | 4.71 | 9.01 | 18.95 | 24.29 | 5.26 | 8.69 | 1.86 | -- | 0.2017 | 31.20 | -8.24 | 4.04 | -26.73 | -0.6127 | 24.20 | -3.77 |
| Shenzhen Chipscreen Biosciences Co Ltd | 547.79m | 103.01m | 9.02bn | 1.06k | 85.81 | 5.34 | -- | 16.47 | 0.2578 | 0.2578 | 1.33 | 4.15 | 0.1761 | 1.66 | 3.97 | 518,248.70 | 2.14 | 1.32 | 2.61 | 1.54 | 86.99 | 93.29 | 12.17 | 6.97 | 2.99 | -- | 0.4037 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.29bn | -15.12m | 9.20bn | 2.70k | -- | 2.28 | -- | 7.16 | -0.0368 | -0.0368 | 3.27 | 10.07 | 0.2191 | 0.9761 | 2.85 | 476,061.10 | -0.286 | 13.16 | -0.3724 | 15.92 | 71.31 | 70.50 | -1.31 | 23.92 | 2.97 | -- | 0.2154 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Aurisco Pharmaceutical Co Ltd | 1.30bn | 325.73m | 9.33bn | 1.52k | 28.61 | 4.49 | -- | 7.20 | 0.803 | 0.803 | 3.18 | 5.12 | 0.5404 | 1.17 | 4.99 | 852,082.90 | 13.57 | 12.40 | 16.46 | 14.33 | 56.90 | 51.26 | 25.12 | 23.05 | 1.72 | -- | 0.116 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 10.04bn | -76.94m | 9.34bn | 8.06k | -- | 1.13 | -- | 0.9303 | -0.0823 | -0.0823 | 8.45 | 6.86 | 0.5535 | 3.32 | 4.53 | 1,244,871.00 | -0.5084 | 1.95 | -0.8569 | 3.77 | 38.35 | 40.58 | -0.9187 | 3.43 | 0.6303 | -- | 0.4158 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Zhejiang Medicine Co., Ltd. | 8.04bn | 425.74m | 9.61bn | 6.23k | 22.28 | 0.9835 | -- | 1.20 | 0.447 | 0.447 | 8.41 | 10.13 | 0.6329 | 2.91 | 5.57 | 1,290,409.00 | 2.14 | 4.32 | 2.75 | 5.68 | 31.16 | 36.57 | 3.39 | 6.28 | 1.62 | 5.95 | 0.0819 | 58.72 | -3.96 | 2.59 | -20.37 | 3.34 | 12.65 | 0.00 |
| Shanghai Runda Medical Technology Co Ltd | 9.04bn | 214.86m | 9.74bn | 3.32k | 43.72 | 2.25 | -- | 1.08 | 0.3719 | 0.3719 | 15.65 | 7.22 | 0.6219 | 4.66 | 1.56 | 2,727,524.00 | 2.55 | 4.78 | 7.04 | 12.86 | 26.02 | 27.13 | 4.10 | 6.36 | 1.06 | 7.84 | 0.5568 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
Data as of May 31 2024. Currency figures normalised to Nanjing Vazyme Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
12.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 4.45m | 2.67% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 3.54m | 2.12% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 2.61m | 1.56% |
| Zheshang Fund Management Co., Ltd.as of 30 Jun 2023 | 2.27m | 1.36% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.05m | 1.23% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 1.49m | 0.90% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.42m | 0.85% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 1.18m | 0.71% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.12m | 0.67% |
| Tian Hong Asset Management Co., Ltd.as of 31 Dec 2023 | 1.08m | 0.65% |
More ▼
Data from 30 Jun 2023 - 30 May 2024Source: FactSet Research Systems Inc.
